Evidence map›Paper›PMID 25274805›Full record

ArticleClinical and vaccine immunology : CVI2014

Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome.

Christian Selinger, Natasa Strbo, Louis Gonzalez, Lauri Aicher, Jeffrey M Weiss, G Lynn Law, Robert E Palermo, Monica Vaccari, Genoveffa Franchini, Eckhard R Podack and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Christian SelingerDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Natasa StrboDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Louis GonzalezDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Lauri AicherDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Jeffrey M WeissDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
G Lynn LawDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Robert E PalermoDepartment of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA.
Monica VaccariAnimal Models and Retroviral Vaccines, National Cancer Institute, Bethesda, Maryland, USA.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines, National Cancer Institute, Bethesda, Maryland, USA.
Eckhard R PodackDepartment of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Michael G KatzeDepartment of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA honey@uw.edu.
University of Washington · USUniversity of Miami · USNational Cancer Institute · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Miami Clinical and Translational Science InstituteKL2TR000461 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$2.1M
Response to and protection by gp96SIVIg/TNFSF13 and gp96SIVIg/TNFSF15 vaccinesP01AI096396 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI PODACK, ECKHARD R · 2011 to 2011
$2.0M
NCATS NIH HHS KL2 TR000461NIAID NIH HHS HHSN272201300010CNIAID NIH HHS HHSN272201300010INIAID NIH HHS P01 AI096396NIAID NIH HHS P01AI096396NIH HHS P51 OD010425PHS HHS N01-A30018PHS HHS P510D010425
6 · The paper itself

Abstract

Using whole-blood transcriptional profiling, we investigated differences in the host response to vaccination and challenge in a rhesus macaque AIDS vaccine trial. Samples were collected from animals prior to and after vaccination with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp96-Ig loaded with simian immunodeficiency virus (SIV) peptides, either alone or in combination with a SIV-gp120 protein boost. Additional samples were collected following multiple low-dose rectal challenges with SIVmac251. Animals in the boosted group had a 73% reduced risk of infection. Surprisingly, few changes in gene expression were observed during the vaccination phase. Focusing on postchallenge comparisons, in particular for protected animals, we identified a host response signature of protection comprised of strong interferon signaling after the first challenge, which then largely abated after further challenges. We also identified a host response signature, comprised of early macrophage-mediated inflammatory responses, in animals with undetectable viral loads 5 days after the first challenge but with unusually high viral titers after subsequent challenges. Statistical analysis showed that prime-boost vaccination significantly lowered the probability of infection in a time-consistent manner throughout several challenges. Given that humoral responses in the prime-boost group were highly significant prechallenge correlates of protection, the strong innate signaling after the first challenge suggests that interferon signaling may enhance vaccine-induced antibody responses and is an important contributor to protection from infection during repeated low-dose exposure to SIV.

Indexed as

AIDS VaccinesAnimalsAntibodies, ViralFemaleHost-Pathogen InteractionsMacaca mulattaMaleSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccinationAIDS VaccinesAntibodies, ViralSAIDS Vaccines

Identifiers

PMID25274805
PMCPMC4248781
OpenAlexW1963900588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.